Guggenheim Begins Coverage on Yarrow Bioscience (NASDAQ:YARW)

Analysts at Guggenheim started coverage on shares of Yarrow Bioscience (NASDAQ:YARW) in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $60.00 price target on the stock. Guggenheim‘s price objective indicates a potential upside of 341.18% from the stock’s previous close.

Several other research analysts have also recently weighed in on the company. TD Cowen began coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They set a “buy” rating for the company. BTIG Research assumed coverage on shares of Yarrow Bioscience in a research report on Monday, August 3rd. They issued a “buy” rating and a $58.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Yarrow Bioscience to a “hold” rating in a research report on Saturday, August 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.00.

Yarrow Bioscience Price Performance

Shares of NASDAQ YARW opened at $13.60 on Friday. The firm’s fifty day moving average price is $23.78. Yarrow Bioscience has a 1 year low of $12.39 and a 1 year high of $46.95.

Yarrow Bioscience (NASDAQ:YARW) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Braidwell LP bought a new stake in shares of Yarrow Bioscience during the 2nd quarter worth $596,000. Susquehanna International Group LLP acquired a new position in shares of Yarrow Bioscience in the 2nd quarter worth $77,000. Two Sigma Securities LLC acquired a new position in shares of Yarrow Bioscience in the 2nd quarter worth $26,000. Nantahala Capital Management LLC acquired a new position in shares of Yarrow Bioscience in the 2nd quarter worth $1,301,400,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Yarrow Bioscience during the second quarter worth $1,920,000. Institutional investors own 83.78% of the company’s stock.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.